Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF-AS
NCT07539259Phase 2Not yet recruiting
- Sponsor
- University College London
- Start
- Dec 2026
- Primary completion
- Aug 2029
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of dapagliflozin, spironolactone in aortic stenosis (AS), sponsored by University College London. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
dapagliflozinspironolactone
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on NCT07539259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07539259.